Navigation Links
EntreMed Focuses on Development of ENMD-2076
Date:12/15/2008

Operations and Management Realigned to Provide Full Support for Clinical Activities

ROCKVILLE, Md., Dec. 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company announced today plans to focus the Company's resources on its most promising near-term product candidate, ENMD-2076, an Aurora/angiogenesis kinase inhibitor, as part of the Company's overall plan to lower operating costs and preserve capital. The plan calls for acceleration of the Company's 2009 clinical objectives for ENMD-2076, effectively transitioning the Company into a clinically-focused operation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a unique small molecule kinase inhibitor which, in preclinical studies, has displayed an excellent activity profile and is currently in Phase 1 clinical trials for solid tumors and multiple myeloma. The Company expects to have available clinical data in mid-2009. While the Company's other product candidates, including MKC-1, ENMD-1198 and Panzem(R) in rheumatoid arthritis, continue to be promising, the Company will consider further clinical development only if additional financial resources are available. As a result, the Company expects to reduce all research activities to the minimal level necessary to continue its efforts to realize their potential value through arrangements with third parties. The Company's plan for these programs is not expected to affect ongoing trials and current patients.

Carolyn F. Sidor, M.D., M.B.A., Vice President, and Chief Medical Officer, will continue to lead the clinical development of ENMD-2076. Mark R. Bray, Ph.D, Vice President Research, will lead the research support for the Company'
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. EntreMed Reports Clinical Program Progress and Company Update
2. EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
3. EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program
4. EntreMed to Present at the BIO 2008 Annual International Convention
5. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
6. EntreMed Reports First Quarter 2008 Financial Results
7. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
10. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
11. EntreMed Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... 2015 , ... Brig and Lita Hart, icons of the network marketing industry ... Home mission with the HOPE Movement of EvolvHealth. In what has been a long-term ... agreed to join their missions of purpose together to change the course of the ...
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, which ... Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the ... message including ones already sent. , While text messaging has more features than it ...
(Date:7/31/2015)... ... ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened a regional ... 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and Latin America(1) ... and Allied Health Personnel Development, Unit of Human Resources for Health, Department of Health ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin ... re-branded their social media profiles to better connect with the public. The agency ... find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to ...
Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2
... with high amount of dietary fiber may eventually lowers a protein, ... foodconsumer.org, the study involving 524 health women and men found that ... of C-reactive protein (CRP) in their blood than those who ate ... inflammation in the body, is regarded as a risk factor for ...
... & Lomb Inc. is in the eye of a storm. ... to ascertain the reason// behind a strange fungus infection among ... parts of Asia. ,Bausch & Lomb, who are ... the cause of Fusarium keratitis infections is not emanating from ...
... elders to slip into the past and reminisce about the ... that such frequent reminiscing of the past could make you ... when an elderly relative starts living completely in the past ... from older relatives repeating boring old yarns, it is not ...
... A hormone called brain natriuretic peptide can predict the ... disease, according to a study appearing in the April ... Care Medicine, published by the American Thoracic Society. ... in the Department of internal medicine at Ludwig Maximillians ...
... test the drug manufactured by German pharmaceutical company TeGenero by ... which was designed to treat rheumatoid arthritis, leukaemia and multiple ... six men who fell seriously ill after taking part in ... like his brain was on fire. Student Nav Modi, 24, ...
... has been shown that babies who were given an aid ... consequences and is safe. The way was CNEP therapy - ... assessed by unconnected Nottingham researchers to the original trial in ... Stoke-based paediatrician Professor David Southall. ,The Nottingham researchers ...
Cached Medicine News:Health News:High Dietary Fiber Reduce The Risk Of Heart Disease 2Health News:Reminiscing Into The Past Makes You Dissatisfied With The Present 2
(Date:7/31/2015)... July 31, 2015 According to a ... (Moist Heat, Dry Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services ... (Hospitals, Pharmaceuticals) - Global Forecast to 2020", published by MarketsandMarkets, ... 6.1 Billion by 2020, at a CAGR of 7.6%.from 2015 ... market data T ables and 37 ...
(Date:7/31/2015)... and SAN DIEGO , July 31, ... company Eisai Co., Ltd. (Headquarters: Tokyo ... and Halozyme Therapeutics, Inc. (Headquarters: San Diego, ... Torley , "NASDAQ: HALO") have signed a clinical collaboration ... ® , "eribulin") in combination with Halozyme,s investigational drug ...
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 4% as currency reduced sales growth ... per diluted share as reported (EPS) were $2.73, compared ... $2.80 , an increase of 9% over the ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... , Feb. 4 Accuray Incorporated (Nasdaq: ARAY ), ... for the second quarter of fiscal year 2010, ended December 31, ... reported total revenue of $57.3 million , compared to the second ... , Accuray reported a net loss for the second quarter of fiscal ...
... , , ATLANTA , Feb. ... for Economic and Clinical Health (HITECH) Act, Elekta has expanded its ... advantage of the financial incentives available from the federal government. These ... certified EMR systems who are able to demonstrate meaningful use. , ...
Cached Medicine Technology:Accuray Announces Results for Second Quarter Fiscal 2010 2Accuray Announces Results for Second Quarter Fiscal 2010 3Accuray Announces Results for Second Quarter Fiscal 2010 4Accuray Announces Results for Second Quarter Fiscal 2010 5Accuray Announces Results for Second Quarter Fiscal 2010 6Accuray Announces Results for Second Quarter Fiscal 2010 7Accuray Announces Results for Second Quarter Fiscal 2010 8Accuray Announces Results for Second Quarter Fiscal 2010 9Accuray Announces Results for Second Quarter Fiscal 2010 10Accuray Announces Results for Second Quarter Fiscal 2010 11Accuray Announces Results for Second Quarter Fiscal 2010 12Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 2Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 3
Provides outstanding patient warming and safety throughout the hospital and is nearly half the size and one-third the weight of earlier units....
The SnuggleWarm Convective Warming provides the technology and the tools to effectively enhance the quality of patient care....
The product, which is comprised of a non-intrusive panty-liner, offers a simple to use classification tool that uses color identification for interpretation of the results....
The Affirm™ VPIII tests RNA probe technology offers a dependable, rapid means toward early identification and treatment of patients suffering from these pathogens....
Medicine Products: